Evox Therapeutics company

Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
Technology: Regenerative Medicine
Industry: Regenerative medicine
Headquarters: Oxford, Oxfordshire, United Kingdom
Founded Date: 7-8
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 9
Total Funding: £47.2M
Estimated Revenue: $10M to $50M
Last Funding Type: Grant

Visit Website
enquiries@evoxtherapeutics.com
@evox_ltd
Register and Claim Ownership